Search the Newsreel

Meghmani Organics profit surges 280% as margins expand to 18% in Q1FY27

Colgate Palmolive (India) shares decline 2.07%

4D Molecular Therapeutics (FDMT) to Announce Earnings on Monday

4D Molecular Therapeutics (FDMT) is set to release its Q2 2026 earnings before market open on Monday, August 10th, with analysts expecting a loss of $1.04 per share and revenue of $3.62 million. The company's shares have recently declined by 3.3%, and the stock …

Moleculin Biotech completes $9.3M equity financing

Moleculin Biotech Raises $9.3 Million Equity; Signs Placement, Purchase and Lock-Up Agreements

Moleculin Biotech successfully completed a public offering, raising approximately $9.3 million gross. The company entered into a Placement Agency Agreement with Roth Capital Partners and a Securities Purchase Agreement with investors. Additionally, directors and officers have agreed to 60-day lock-up periods following the closing, …

FDMT (FDMT) investor David Kirn plans Rule 144 sale of 12,415 shares

David Kirn, a shareholder in 4D Molecular Therapeutics, Inc. (FDMT), has filed a Rule 144 notice to sell 12,415 shares of Class A Common Stock through Goldman Sachs & Co. LLC on or after August 3, 2026. The proposed sale has an aggregate market …

Colgate-Palmolive’s Q2 Earnings Beat on Nearly Every Line But Free Cash Flow Stole the Show.

Enterprise value to EBIT forward of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT

The article provides a financial metric, "Enterprise value to EBIT forward," for 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT). This information is sourced from TradingView, which offers various financial data and tools for market analysis. The content primarily focuses on presenting this specific financial ratio …

Form 424B5 Moleculin Biotech Inc For: 3 August By Investing.com

This article announces the filing of Form 424B5 by Moleculin Biotech Inc., specifically for August 3rd. It is a brief, informative post from Investing.com, likely notifying investors of a regulatory filing by the company. The text reiterates the main point multiple times without further …

JPMorgan Chase & Co. Lowers Colgate-Palmolive (NYSE:CL) Price Target to $103.00

JPMorgan Chase & Co. has reduced its price target for Colgate-Palmolive (NYSE:CL) from $104.00 to $103.00, while maintaining an "overweight" rating. This new price target suggests a potential upside of 12.76% from the company's previous closing price. Other analysts have also recently updated their …

RBC Capital raises Colgate-Palmolive stock price target on profit execution

RBC Capital increased its price target for Colgate-Palmolive (NYSE:CL) to $104 from $102, maintaining an Outperform rating due to strong profit execution despite mixed quarterly results. The company's gross profit margin of 60.43% was highlighted as a key strength, alongside an EPS beat driven …

Moleculin Biotech, Inc. SEC Filing (Aug 3, 2026)

This article reports on a Moleculin Biotech, Inc. (MBRX) SEC filing, specifically an EFFECT filing, which had a neutral impact and sentiment. The filing pertains to the effectiveness of an S-1 registration statement for the company, dated July 31, 2026. The article also provides …

TD Cowen raises Colgate-Palmolive stock price target on margin beat

TD Cowen has increased its price target for Colgate-Palmolive (NYSE:CL) stock to $90 from $

UBS Adjusts Price Target on Colgate-Palmolive to $109 From $106, Maintains Buy Rating

UBS has increased its price target for Colgate-Palmolive (CL) to $109 from $106, while maintaining a Buy rating on the stock. This adjustment comes amidst several other analyst revisions for Colgate-Palmolive on the same day, with most firms raising their price targets and maintaining …

Colgate Reports Strong Second Quarter 2026 Results

Colgate-Palmolive announced strong second-quarter 2026 financial results, with net sales increasing by 4.9% to $5.36 billion and adjusted earnings per share exceeding analyst expectations. The company saw regional growth in Latin America, Europe, the Middle East, Africa, and Asia-Pacific, while North America experienced a …

Colgate-Palmolive Company (CL) PT Raised to $90 at TD Cowen

TD Cowen analyst Robert Moskow has increased the price target for Colgate-Palmolive Company (NYSE: CL) to $90.00 from $85.00. This update indicates a positive outlook from the analyst for the consumer products giant. The article provides this key analyst action without further details, as …

Moleculin Biotech Reports Positive Pivotal Phase 2/3 Trial Results for Annamycin in AML

Moleculin Biotech announced positive updated preliminary blinded results from Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin in combination with cytarabine (AnnAraC) for relapsed or refractory acute myeloid leukaemia (R/R AML). The therapy showed strong remission rates, including in venetoclax-pretreated patients, …

RBC Capital Adjusts Colgate-Palmolive PT to $104 From $102, Maintains Outperform Rating

RBC Capital has increased its price target for Colgate-Palmolive (CL) to $104 from $102, while reiterating an Outperform rating on the stock. This adjustment comes amidst a series of analyst recommendations for Colgate-Palmolive, with several firms updating their price targets and ratings. The company …

Colgate-Palmolive Company $CL Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. reduced its stake in Colgate-Palmolive (NYSE:CL) by 5.7% in the first quarter, selling 148,594 shares but still retaining over 2.45 million shares valued at approximately $208.9 million. This comes as Colgate-Palmolive reported strong second-quarter adjusted EPS and revenue growth, though GAAP …

Jefferies raises Colgate-Palmolive stock price target on emerging markets strength

Jefferies has increased its price target for Colgate-Palmolive (NYSE:CL) to $89 from $88, citing strong performance in emerging markets. Despite a "Hold" rating, the firm acknowledges Colgate-Palmolive as a prime way to access emerging market growth within U.S. household and personal care equities. However, …

Molina Healthcare Inc (MOH) Stock Analysis: Navigating a 6.90% Potential Upside Amidst Mixed Performance Metrics

Molina Healthcare Inc (MOH) presents a complex investment case with a potential upside of 6.90% to an average target price of $209.12. Despite serving a critical demographic in healthcare, the company faces concerns due to a 5.70% decline in revenue and a slightly negative …

Morgan Stanley Adjusts PT on Colgate-Palmolive to $104 From $100, Maintain Overweight Rating

Morgan Stanley has increased its price target on Colgate-Palmolive (CL) to $104 from $100, while maintaining an "Overweight" rating on the stock. This adjustment comes after Colgate-Palmolive reported its Q2 2026 earnings, with the company also reaffirming its annual sales forecast and updating its …

Carmignac Gestion Cuts Stock Holdings in Colgate-Palmolive Company $CL

Carmignac Gestion significantly reduced its stake in Colgate-Palmolive Company (NYSE:CL) by 79.5% in the first quarter, selling over 900,000 shares. Despite this reduction by one institutional investor, other funds like Teacher Retirement System of Texas and Mirae Asset Global Investments Co. Ltd. increased their …

IGIL targets 17-19% revenue CAGR, cites SUV surge

Colgate-Palmolive Company (CL) PT Raised to $89 at Jefferies

Jefferies analyst Kaumil Gajrawala increased the price target for Colgate-Palmolive Company (NYSE: CL) to $89.00 from $88.00. The analyst maintained a rating on the stock. This article is a premium-only content piece, requiring a subscription to StreetInsider.com Premium to view in full.

Colgate-Palmolive: Base Business EPS Increases 8% As Gross Margin Expands 140 Basis Points

Colgate-Palmolive reported an 8% increase in Base Business EPS for Q2 2026, reaching $0.99, driven by gross margin expansion, organic sales growth, and improved operating profit. This occurred despite a 5% decline in reported EPS due to costs from its Strategic Growth and Productivity …

Bronstein, Gewirtz & Grossman, LLC Encourages Molina Healthcare, Inc. (MOH) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Molina Healthcare, Inc. (MOH) securities who bought shares before February 5, 2025, and still hold them. The investigation aims to determine if Molina and its officers engaged in corporate wrongdoing. …

Moleculin Biotech (MBRX) Registration filing Summary

Moleculin Biotech (MBRX) has filed a registration for a stock and warrant offering to raise $9.1 million, aiming to advance its late-stage cancer drug, Annamycin, for relapsed/refractory acute myeloid leukemia (AML). As of March 31, 2026, the company's net tangible book value was $4.0 …

MOH5939489 Bond Profile — Key Metrics

This article provides a bond profile for Molina Healthcare, Inc. 6.25% 15-JAN-2033 (MOH5939489), detailing key metrics such as issue date, maturity date, outstanding amount, face value, and coupon rate. It identifies Molina Healthcare as a healthcare services provider with segments including Medicaid, Medicare, and …

First Nebraska Trust Co Takes $5.16 Million Position in Colgate-Palmolive Company $CL

First Nebraska Trust Co. has acquired a new stake worth approximately $5.16 million in Colgate-Palmolive Company, purchasing 60,532 shares. This comes as Colgate-Palmolive reported strong Q2 earnings, beating analyst estimates with $0.99 EPS and a 4.9% increase in revenue. Despite positive financial results and …

Mold-Tek Packaging raises FY27 EBITDA per kg target to ₹44-45

Colgate-Palmolive (CL) Stock Sees Revenue Strength Clash With Margin Strain

Colgate-Palmolive (CL) is experiencing revenue growth, particularly in premium oral care, pet nutrition, and emerging markets, with Q2 2026 net sales up mid-single digit. However, profitability remains a concern, with a trailing 12-month net margin of 10% compared to 14.5% the previous year, and …

Colgate-Palmolive Company $CL Stock Position Cut by Vestor Capital LLC

Vestor Capital LLC significantly cut its stake in Colgate-Palmolive (CL) by 95.1% in Q1 2026, selling over 30,000 shares but still retaining 1,560 shares. Despite this, other institutional investors increased their positions, and 80.41% of the stock is held by institutions. The article also …

Qué significan para los accionistas la reducción de los márgenes y las previsiones estables de Colgate-Palmolive (CL) para el segundo trimestre de 2026

Was der Margenrückgang im zweiten Quartal 2026 und die unveränderte Prognose von Colgate-Palmolive (CL) für die Aktionäre bedeuten

Colgate Palmolive (CL) Stock Trades At A Cash Flow Discount Despite An Earnings Premium